Armistice Capital’s GSK GSK Stock Holding History

Armistice Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13M	Sell	236,000 -764,000	-76%	-$41.4M	0.23%	77
2025 Q4	$49M	Buy	+1,000,000	New	+$46.6M	0.58%	26
2025 Q2	–	Sell	-378,000	Closed	-$14.6M	–	229
2025 Q1	$14.6M	Sell	378,000 -2,000,000	-84%	-$73.2M	0.22%	81
2024 Q4	$80.4M	Buy	2,378,000 +1,854,000	+354%	+$66.7M	1.1%	12
2024 Q3	$21.4M	Sell	524,000 -976,000	-65%	-$39.9M	0.34%	52
2024 Q2	$57.8M	Buy	1,500,000 +536,000	+56%	+$22.5M	0.73%	18
2024 Q1	$41.3M	Sell	964,000 -1,232,000	-56%	-$50.8M	0.55%	34
2023 Q4	$81.4M	Buy	2,196,000 +1,911,000	+671%	+$68.6M	1.11%	9
2023 Q3	$10.3M	Sell	285,000 -15,000	-5%	-$532K	0.16%	87
2023 Q2	$10.7M	Sell	300,000 -2,936,000	-91%	-$105M	0.15%	91
2023 Q1	$115M	Buy	3,236,000 +180,000	+6%	+$6.3M	1.66%	10
2022 Q4	$107M	Sell	3,056,000 -544,000	-15%	-$18.1M	1.87%	11
2022 Q3	$106M	Buy	+3,600,000	New	+$136M	1.84%	11
2018 Q1	–	Sell	-329,600	Closed	-$14.6M	–	73
2017 Q4	$14.6M	Buy	+329,600	New	+$15.2M	1.46%	23

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Armistice Capital's GSK Position: Q1 2026 in Review

Armistice Capital reduced its GSK (GSK) stake by 76% in Q1 2026, selling an estimated $41.4M and leaving 236,000 shares worth $13M. The position accounts for 0.23% of the portfolio, ranked #77.

Armistice Capital first reported a position in GSK in Q4 2017 and has held it in 14 quarters since. The position peaked at $115M in Q1 2023. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Armistice Capital held 236,000 shares of GSK worth $13M as of Q1 2026.
Armistice Capital sold 764,000 GSK shares in Q1 2026, an estimated $41.4M.
GSK made up 0.23% of Armistice Capital's portfolio in Q1 2026, its #77 holding.
Armistice Capital first reported a position in GSK in Q4 2017 and has held it in 14 quarters since.
Armistice Capital's GSK position peaked at $115M in Q1 2023.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.